DGAP-News: CTS Eventim AG & Co. KGaA / Key word(s): Miscellaneous
CTS EVENTIM supports German Cancer Research Centre with one million
Euro for an endowed chair
06.05.2015 / 10:02
---------------------------------------------------------------------
PRESS RELEASE
CTS EVENTIM supports German Cancer Research Centre with one million Euro
for an endowed chair
CTS EVENTIM, Europe's biggest provider of ticketing services, will finance
an endowed chair in 'Epigenetic Regulation' at the German Cancer Research
Centre (Deutsches Krebsforschungszentrum - DKFZ). The company will donate a
total of one million Euro over a five-year period, according to a recent
agreement concluded by Klaus-Peter Schulenberg, CEO of CTS EVENTIM, and the
Management Board of the DKFZ.
Bremen, 6 May 2015. Our paramount aim in giving this financial support is
to help in the important struggle against cancer. Supporting cutting-edge
research in Germany is also close to our heart. The DKFZ's outstanding work
makes it an ideal partner for both these concerns', says Klaus-Peter
Schulenberg about his company's commitment.
'We are delighted that the generous endowment by CTS EVENTIM will allow us
to give a brilliant young talent the opportunity of taking up a chair at
our centre', says Professor Otmar D. Wiestler, Chairman of the Management
Board of the German Cancer Research Centre. 'In a joint effort with the
University of Heidelberg, we shall initiate an appointment procedure very
soon so that a highly qualified candidate is recruited as quickly as
possible.'
In their search, the DKFZ and the university will focus on young talents
with an innovative and original research approach, with which they can also
compete at international level.
'Cutting-edge research costs a lot of money, so even when it is supported
by the public sector it is reliant more than ever before on support from
private-sector donors', says Professor Josef Puchta, the Administrative and
Commercial Director of the German Cancer Research Centre. 'Sourcing
private-sector money for research is still uncommon in Germany. In the USA
or Israel, in contrast, there is a strong tradition of supporting research
in this way. Our hope is therefore that the wonderful example set by CTS
EVENTIM will be emulated by very many others', says Puchta.
CTS EVENTIM AG & Co. KGaA, which is listed in the MDAX segment, is Europe's
market leader in the ticketing field, with operations in 23 countries, and
one of the leading providers of live entertainment. More than 100 million
tickets for over 200,000 events are sold annually using systems developed
and marketed by the EVENTIM Group. CEO Klaus-Peter Schulenberg has been
actively involved for many years in the Advisory Council of the German
Cancer Research Council, which is chaired by Professor Roland Berger.
For further information:
Engel & Zimmermann AG, Unternehmensberatung für Kommunikation
Dr. Andreas Bachmeier, Tel. +49 89 8935 633, info@engel-zimmermann.de
---------------------------------------------------------------------
06.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: CTS Eventim AG & Co. KGaA
Dingolfinger Str. 6
81673 München
Germany
Phone: 0421/ 3666-233
Fax: 0421/ 3666-290
E-mail: sarah.trede@eventim.de
Internet: www.eventim.de
ISIN: DE0005470306
WKN: 547030
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
353611 06.05.2015
DGAP-News: CTS EVENTIM supports German Cancer Research Centre with one million Euro for an endowed chair
| Source: EQS Group AG